E Fund Management Co. Ltd. Buys 1,755 Shares of Johnson & Johnson (NYSE:JNJ)

E Fund Management Co. Ltd. increased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 12.2% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 16,173 shares of the company’s stock after purchasing an additional 1,755 shares during the quarter. E Fund Management Co. Ltd.’s holdings in Johnson & Johnson were worth $2,364,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the stock. Gilbert & Cook Inc. boosted its stake in Johnson & Johnson by 3.3% in the fourth quarter. Gilbert & Cook Inc. now owns 9,111 shares of the company’s stock valued at $1,428,000 after acquiring an additional 288 shares during the last quarter. 9258 Wealth Management LLC boosted its stake in Johnson & Johnson by 2.1% in the fourth quarter. 9258 Wealth Management LLC now owns 22,034 shares of the company’s stock valued at $3,454,000 after acquiring an additional 443 shares during the last quarter. Gryphon Financial Partners LLC boosted its stake in Johnson & Johnson by 66.3% in the fourth quarter. Gryphon Financial Partners LLC now owns 14,245 shares of the company’s stock valued at $2,244,000 after acquiring an additional 5,680 shares during the last quarter. Brown Advisory Inc. boosted its stake in Johnson & Johnson by 0.5% in the fourth quarter. Brown Advisory Inc. now owns 1,011,729 shares of the company’s stock valued at $158,578,000 after acquiring an additional 5,233 shares during the last quarter. Finally, Windle Wealth LLC boosted its stake in Johnson & Johnson by 3.5% in the fourth quarter. Windle Wealth LLC now owns 37,202 shares of the company’s stock valued at $5,831,000 after acquiring an additional 1,266 shares during the last quarter. 69.55% of the stock is owned by institutional investors.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction on Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the sale, the vice president now directly owns 18,973 shares in the company, valued at approximately $3,131,683.38. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. The Goldman Sachs Group cut their target price on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a report on Friday, July 19th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a report on Monday. Daiwa America lowered shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 23rd. Morgan Stanley increased their target price on shares of Johnson & Johnson from $167.00 to $169.00 and gave the stock an “equal weight” rating in a report on Thursday, July 18th. Finally, StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday. Seven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $173.21.

Johnson & Johnson Trading Up 0.0 %

Shares of NYSE:JNJ opened at $167.07 on Wednesday. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $168.85. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.44. The company’s fifty day simple moving average is $160.38 and its 200 day simple moving average is $154.01. The firm has a market cap of $402.08 billion, a price-to-earnings ratio of 10.42, a PEG ratio of 2.71 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The firm had revenue of $22.45 billion for the quarter, compared to analyst estimates of $22.33 billion. During the same period in the previous year, the business earned $2.80 EPS. The company’s revenue was up 4.3% compared to the same quarter last year. As a group, research analysts forecast that Johnson & Johnson will post 10.02 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th were paid a $1.24 dividend. The ex-dividend date was Tuesday, August 27th. This represents a $4.96 annualized dividend and a yield of 2.97%. Johnson & Johnson’s payout ratio is currently 30.92%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.